Aravive Inc

Aravive — Investor Presentation (August 2021)

40 slides from Aravive's investor presentation, Aug 9, 2021

  1. Slide 1: Halting Disease Progression in its Tracks

    ¢°9 aravive Halting Corporate Presentation Disease August 2021 Progression : ARAV (NASDAQ) in its Tracks hg © 2021 Aravive, inc. in

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward: looking statements generally include statements tha

  3. Slide 3: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases

    Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival ] AVB-500 development program focused on difficult-to-treat cancers with high unmet medical needs ] AVB-500 has potential in multiple indications and multiple therapeutic combinations Proprietary

  4. Slide 4: Experienced Management and Board of Directors

    Experienced Management and Board of Directors Senior Management HAtoitanwn cMo cro SVP of Data Sciences VP, Regulatory YP. Translational Medicine GailMelnyte, PhD, Reshma Rangwola M.D. Vinay Shon Randy Anderson, Ph.D. Jody Gould, PRO. Elisabeth Gardiner, Ph.D. ABT Ph. Board of Directors R@20HHOS Cha

  5. Slide 5: AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway

    AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway and Blocking the Signaling Ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway Granted FDA Fast Track Designation in Platinum Resistant Ovarian Cancer (PROC) Neutralizes GAS6, starving tumors of AVB-500

  6. Slide 6: GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth

    GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth GAS6 and AXL are overexpressed in many Causesimmune Dives Resistance to Chemotherapy, Canosts antiasanciated wit imiargrowitl Suppression Radar, Tae They, metastasis, drug resistance, and poor overall survival + GAS6 is growth factor that regul

  7. Slide 7: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers

    GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in >70% of ovarian, pancreatic, breast, kidney, and uterine cancers” “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Si Gt 1 Mleaarnsightsof Gos6/TAMin concer developmental Cel Dea

  8. Slide 8: AVB-500: Addresses Limitations of Other Therapies

    \VB-500: Addresses Limitations of Other Therapies As an engineered decoy receptor with 200-fold MPANY STAGE) tarcer SELECTIVE higher affinity for GAS6 versus natural OREN GAS6/AXL interaction, AVB-500 provides Aravive AVB-500 (Ph 3) GASE YES potent & selective inhibition of this signaling "Astillas:

  9. Slide 9: Clinical Pipeline

    Clinical Pipeline Potential Opportunities for Expansion in Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 2 Phase 3 AVB-500 ‘OVARIAN CANCER CLEAR CELL RENAL CANCER PANCREATIC ADENOCARCINOMA, AVB-500 Investigator Sponsored Trials OVARIAN CANCER Bispecific Antibodies

  10. Slide 10: Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer

    Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality @ Ovarian Cancer ©2021 Aravive, Inc 5th ~21,400 ~314,000 ~70% 50% eo LEADING CAUSE OF DEATH among women in the U.S. NEW CASES and ~13,800 deaths expected in the U.S. in 2021 NEW CASES

  11. Slide 11: AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data

    AVB-500 q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m dof 28-day cycle; Paclitaxel (PAC) 80 mg/m? day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on AVB-500 monotherapy IDMC Review IDMC Review Select ‘RP2D 'RP2D= Recommend P2 Dose ©2021 Aravive, Inc eo \VB-500 PROC: Phase 1a and 1b

  12. Slide 12: Time on Treatment and Depth of Response for AVB-500 + Paclitaxel Patients

    Time on Treatment and Depth of Response for AVB-500 + Paclitaxel Patients (10 and 15mg/kg groups) P45 Months or Per Pratl 1g /h9 od 8 maha AVBSOO*PocSibets Largest change in Target Lesion for Per rte 10 mg/h and 1 n/a AME S00 Pac Sbjct 12 ©2021 Aravive, Inc ro)

  13. Slide 13: AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups

    AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups EFFICACY DATA FOR PATIENTS RECEIVING 10MGIKG AND 15MG/KG OF AVB-500 & PACLITAXEL INCLUDING IF BEVACIZUMAB NAIVE OR PREVIOUSLY RECEIVED BEVACIZUMAB >MEC"(N=10) <MEC™ (N=9) Bev Naive (N=9) Previous Bev(N=10) ORR 5 (50%), CRs" 2 (22%) 6 (6

  14. Slide 14: sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo

    sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo SAXL/GASE R. AVB-500 + PAC (10 & 15 ma + Serum levels of sAXL/GASG ratio (potential 773 i nase ADOUOUTE ESON OES biomarker) correlated with response to AVB-500 + N 12 7 Chemo cR 2(17%) ° + Building dataset to understand prognostic ability o

  15. Slide 15: Promising Responses in Patients > MEC with Poor Prognostic Indicators

    Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF AVB-500+CHEMO’ IN PATIENTS CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS. WITH <3MO PLATINUM FREE INTERVAL (N=12) WITH <3MO PLATINUM FREE INTERVAL” (N=21) ie = ie be = 0% f-3 i & a 5 & = ‘ 10% = - = aoe ‘ORR $

  16. Slide 16: Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg

    Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg * Consistent with hypothesis that trough levels are associated with clinical 5/5 patients at 15mg/kg activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their demonstrated clinical benefit: first CT scan, following four dos

  17. Slide 17: Strong Safety Profile of AVB-500

    Strong Safety Profile of AVB-500 53 PROC Patients Dosed: 10 mg/kg (40); 15 mg/kg (6); and 20 mg/kg (7) + Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE

  18. Slide 18: Competitive Advantages of AVB-500 in PROC

    Competitive Advantages of AVB-500 in PROC: Favorable Safety Profile and Compelling Anti-Tumor Activity + Favorable Safety Profile to Date + NO DLTs like chemotherapies and ADCs + NO dose reductions or discontinuations to manage toxicities + NO toxicities that have been seen with ADCs: neutropenia, o

  19. Slide 19: Potentially More Favorable Benefit/Risk Profile vs Competitors

    Potentially More Favorable Benefit/Risk Profile vs Competitors AVB-500+PAC XMT-1536, | Mirvetuxima 10/15mg/kg>MEC Higher NaPi2b/ ALL” | soravtansine, ITT FRa- positive” N 10 31/47 366 (2:1R) ‘ORR 5 (50%) 10(32%) 22% TPR/ CR] [BPRs (30%); 2CRs ISPRs (26%);2CRs [not broken out] (20%)] (6%)1/ 13 (28%)

  20. Slide 20: AVB-500 Phase 3 Adaptive Registration Trial Design in PROC

    AVB-500 Phase 3 Adaptive Registration Trial Design in PROC Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of AVB-500 + PAC versus PAC (ClinicalTrials.gov NCT04729608 ) + FDA Feedback: Study could support full approval in * Primary Endpoint: Progressi

  21. Slide 21: Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma

    Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma; Patients Have Very Poor Survival Rates NEW CASES and ~13,800 deaths expected in the U.S. in 2021 NEW CASES and ~179,400 deaths worldwide in 2020 (e Cell Carcinoma 1S COMMON 5-YEAR RELATIVE SURVIVAL for metastatic renal cancer ©2021 Aravi

  22. Slide 22: Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC

    Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC * GASB6/AXL in clear cell Renal Cell Carcinoma (ccRCC)' 4 |, Y AXL plays significant role in ccRCC invasion & metastasis 100 Bic 5 Y AXL highly expressed in aggressive ccRCC tumors and g al h associated with poor outcome Ea a, ¥ GAS6/AXL

  23. Slide 23: Single Agent Activity in Highly Metastatic Renal Model

    Single Agent Activity in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk Lung Tumor Burden 24 ac # 2 i errs 8 Therapeutic inactivation of AXL significantly reduces the metastatic potential of SN12L1 cells to the lung ©2021 Aravive, Inc 10 mg/kg administered QOD 50.035 2

  24. Slide 24: Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX

    Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX AVB-500/Pazopanib Combination Significantly Reduced Growth Rate in TKI-Resistant Renal Patient-Derived Xenograft Models 14 days after treatment P=0.035 Ete Control Pazopanib AVB-S6 AVB-S6' + Pazopaniy Specific growth rate (hd) ©2

  25. Slide 25: AVB-500 + Cabozantinib Phase 1b/2 Trial Design in ccRCC

    AVB-500 + Cabozantinib Phase 1b/2 Trial Design in ccRCC AVB-500 + Phase 1b Trial of AVB-500 in Combination with Cabozantinib AVB-500 + Up to 18 patients; ability to increase/decrease dose DL-1: 10 makkg DL 1:15 mgikg Q2w based on tolerability, PK/PD DL + Histologically confirmed metastatic ccRCC and

  26. Slide 26: Positive Initial Results from the Phase 1b Portion of the Phase 1b/2 Study

    Positive Initial Results from the Phase 1b Portion of the Phase 1b/2 Study Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15 mg/kg of AVB-500 in combination with Cabozantinib * Data in three evaluable patients showed that AVB-500 was well tolerated with no unexpected findings *

  27. Slide 27: Third Indication: AVB-500 in Pancreatic Adenocarcinoma

    Third Indication: AVB-500 in Pancreatic Adenocarcinoma; High Unmet Medical Need to Improve Patient Survival fox} Pancreatic Cancer ©2021 Aravive, Inc 5-YEAR RELATIVE SURVIVAL Patients with pancreatic cancer have a high mortality rate NEW CASES and ~48,200 deaths expected in the U.S. in 2021 NEW CASE

  28. Slide 28: Strong Biological Rationale for Investigating AVB-500 in Pancreatic Adenocarcinoma

    Strong Biological Rationale for Investigating AVB-500 in Pancreatic Adenocarcinoma as First-Line Therapy in Combination with Gemcitabine + nab-Paclitaxel (Abraxane®) « Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight in

  29. Slide 29: High Affinity AXL Decoy Proteins Decrease Fibrosis, Prolong Survival

    High Affinity AXL Decoy Proteins Decrease Fibrosis, Prolong Survival, and Decrease Tumor Weight Alone or in Combination with Gemcitabine in Pancreatic Models —- Compelling Pre-Clinical Data LM-P Tumor (Kras, p53 mutant) Implanted in Tail of Pancreas PDA1-1 injected IP to establish diffuse metastatic

  30. Slide 30: AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design

    AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Adenocarcinoma Phase 1b Trial of AVB-500 in Combination with Gemcitabine + nab-Paclitaxel AVB-500 * Population: Patients (n= approx. 20) with advanced 2 or metastatic pancreatic

  31. Slide 31: AVB-500 + Gemcitabine + nab-Paclitaxel Phase 2 Trial Design

    AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Adenocarcinoma Planned Controlled, Randomized Phase 2 Trial * Population: Patients (n= approx. 60) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemc

  32. Slide 32: Development Strategy: Conduct Additional Trials to Expand Pipeline

    Development Strategy: Conduct Additional Trials to Expand Pipeline Preclinical data suggests that AVB-500 has potential in multiple combinations and indications: + Combination trials with agents currently embedded as standard of care + Earlier lines of therapy + Multiple tumor types ©2021 Aravive, I

  33. Slide 33: AVB-500: Large Market Opportunities in PROC, ccRCC, Pancreatic Adenocarcinoma

    AVB-500: Large Market Opportunities in PROC, ccRCC, Pancreatic Adenocarcinoma & Other Indications Total Market Ovarian | Renal | Pancreatic | Breast | NSCLC’ | Bladder 2018 $2.38 $3.18 $3.18 $181B $148 $1.68 2028 $0.68 $7.38 $7.38 $4568 $30 $198 Annual Growth Rate 15.6% 9.1% 01% 9.7% 10.8% 28.1% See

  34. Slide 34: Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies

    Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies C9aravive Seog” * Objective is to identify/develop novel, high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), targeting cancer/fibrosis using WuXiBody™ platform v C

  35. Slide 35: 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China

    3D Medicines Collaboration to Develop/Commercialize AVB-500 in China for Oncology Indications esaravive 3DMedcd + Exclusive collaboration and license agreement for development & commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Greater Chin

  36. Slide 36: Financial Summary

    Financial Summary | $75.4 million cash and cash equivalents | Achieved two clinical milestones with 3D Medicines, totaling $9 million 20.4 million shares outstanding No debt Cash runway expected to fund current operating plans into 2H 2022 * pata asorsao2ez1 ©2021 Aravive, Inc ° 38

  37. Slide 37: Aravive Top Shareholders

    Aravive Top Shareholders Eshelman Ventures (Board member) 18.7% Invus Public Equities Advisors 6.5% Tabibiazar, Raymond (Former Board member) 49% New Leaf Biopharma Opportunities 4.7% Giaccia, Amato (Board member) 46% Elite Vantage Global Limited (Board Member) 4.2% BlackRock 3.6% The Vanguard Group

  38. Slide 38: Upcoming Key Milestones Advancing Our Clinical Development Program

    Upcoming Key Milestones Advancing Our Clinical Development Program + Completion of + Interim analysis for + Initiation of + Data from IST- enrollment in Phase Phase 3 PROC trial Phase 2 Pancreatic sponsored trials 1b ccRCC trial (Q1 2022) Adenocarcinoma trial & anti-CTGF (Q3 2021) + Completion of di

  39. Slide 39: Advancing AVB-500 Clinical Trial Program & Pursuing Additional Pipeline Expansion

    Advancing AVB-500 Clinical Trial Program & Pursuing Additional Pipeline Expansion Opportunities Focused on difficult-to-treat cancers: AVB-500 lead indication in advanced stage ovarian cancer; registrational Phase 3 clinical trial ongoing; ccRCC and pancreatic adenocarcinoma Phase 1b clinical trials

  40. Slide 40: Thank you!

    ¢°3 aravive Halting Thank you! Disease Progression in its Tracks S a ©2021 Aravive, nc

Aravive — Investor Presentation (August 2021) on 6ix